Astellas reported vision improvements at low and medium doses in Phase 1b trial of ASP7317, an hESC-derived RPE cell therapy for GA secondary to dry AMD.
ASP7317 Phase Ib trial (7317-CL-0003) is actively enrolling, using dose-escalation from 50,000 to 200,000 cells via subretinal injection, expected to conclude late 2025.
Prior trials (e.g., ASP7316) showed safety, tolerability, and BCVA gains (e.g., +10.4 letters at 24 months in treated eyes vs. +3.8 in untreated).
Astellas plans to present new GA findings at ARVO 2026 Annual Meeting.
Long-term follow-up studies confirm no immune rejection, graft failure, or major safety events, with ongoing surveillance for late-onset AEs.